Phenylketonuria: current dietary treatment practices in the United States and Canada
- PMID: 9100215
- DOI: 10.1080/07315724.1997.10718665
Phenylketonuria: current dietary treatment practices in the United States and Canada
Abstract
Objective: A survey of treatment centers for phenylketonuria (PKU) in the United States and Canada was undertaken regarding current practices of dietary treatment of PKU.
Methods: A total of 111 centers, who follow more than 6,950 patients with PKU responded to the survey.
Results: The majority of the centers, 87%, favor life-long dietary control of phenylalanine intake. The survey found lack of uniformity regarding acceptable range of blood phenylalanine levels. The frequency of clinic visits varied and became less frequent as patients got older. Although most of the clinics recommend diet for life, only one-third of the clinics follow patients beyond the age of 18 years, therefore, it is unclear who manages these patients beyond that age. The survey also showed a high number of families with children who were reported for medical neglect (3.0% compared to < 0.06% in the general population). Because of dietary noncompliance, 1% of the children were removed from the home.
Discussion: The survey points to the common treatment goal of diet for life for patients with PKU and underscores the need for uniform guidelines for achieving this goal.
Similar articles
-
Nutritional management of phenylalanine hydroxylase (PAH) deficiency in pediatric patients in Canada: a survey of dietitians' current practices.Orphanet J Rare Dis. 2019 Jan 8;14(1):7. doi: 10.1186/s13023-018-0978-0. Orphanet J Rare Dis. 2019. PMID: 30621767 Free PMC article.
-
Adherence to clinic recommendations among patients with phenylketonuria in the United States.Mol Genet Metab. 2017 Mar;120(3):190-197. doi: 10.1016/j.ymgme.2017.01.001. Epub 2017 Jan 6. Mol Genet Metab. 2017. PMID: 28162992
-
Management of phenylketonuria for optimal outcome: a review of guidelines for phenylketonuria management and a report of surveys of parents, patients, and clinic directors.Pediatrics. 1999 Dec;104(6):e68. doi: 10.1542/peds.104.6.e68. Pediatrics. 1999. PMID: 10586002
-
Outcomes beyond phenylalanine: an international perspective.Mol Genet Metab. 2010;99 Suppl 1:S79-85. doi: 10.1016/j.ymgme.2009.09.015. Mol Genet Metab. 2010. PMID: 20123476 Review.
-
The reality of dietary compliance in the management of phenylketonuria.J Inherit Metab Dis. 2010 Dec;33(6):665-70. doi: 10.1007/s10545-010-9073-y. Epub 2010 Apr 7. J Inherit Metab Dis. 2010. PMID: 20373144 Review.
Cited by
-
Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine.J Inherit Metab Dis. 2007 Apr;30(2):153-8. doi: 10.1007/s10545-007-0556-4. Epub 2007 Feb 27. J Inherit Metab Dis. 2007. PMID: 17334706 Clinical Trial.
-
Living with phenylketonuria: perspectives of patients and their families.J Inherit Metab Dis. 2005;28(5):639-49. doi: 10.1007/s10545-005-4478-8. J Inherit Metab Dis. 2005. PMID: 16151894
-
Peak bone mass in patients with phenylketonuria.J Inherit Metab Dis. 2007 Apr;30(2):202-8. doi: 10.1007/s10545-007-0462-9. Epub 2007 Mar 8. J Inherit Metab Dis. 2007. PMID: 17347917
-
Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids.Eur J Clin Nutr. 2017 Jan;71(1):51-55. doi: 10.1038/ejcn.2016.166. Epub 2016 Sep 14. Eur J Clin Nutr. 2017. PMID: 27623981 Free PMC article.
-
Large neutral amino acids in the treatment of phenylketonuria (PKU).J Inherit Metab Dis. 2006 Dec;29(6):732-8. doi: 10.1007/s10545-006-0395-8. Epub 2006 Sep 21. J Inherit Metab Dis. 2006. PMID: 16988900
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical